Nelson W. Y. Leung

Aug 28, 2024 | nature.com | Saurabh Zanwar |Jonas Paludo |Ronald S. Go |Joselle M. Cook |Sikander Ailawadhi |Thomas M Habermann | +10 more

An under-recognized source of bleeding in Waldenström macroglobulinemia (WM) is the development of an acquired von Willebrand syndrome (AVWS) [1]. In WM, the von Willebrand Factor (vWF) glycoprotein can be degraded due to autoantibody destruction, increased shear stress due to hyperviscosity, or sequestered due to adsorption onto malignant cells, leading to the development of AVWS (AVWS-WM) [1, 2].

Aug 11, 2024 | nature.com | Razan Mohty |Radhika Bansal |Urshila Durani |Madiha Iqbal |Yucai Wang |Jonas Paludo | +8 more

Dear Editor,Hemophagocytic lymphohistiocytosis (HLH) is a rare complication of chimeric antigen receptor T-cell (CAR-T) therapy [1,2,3]. With the increasing use of CAR-T therapy in treating hematological malignancies, the unique phenomenon of CAR-T-associated HLH (carHLH) is increasingly recognized. Albeit rare, reported rates vary from 1–3% to 35% depending on the underlying disease, patient population and the CAR-T product [1,2,3].

Mar 29, 2023 | nature.com | Nelson W. Y. Leung |S. Vincent Rajkumar

AbstractLight chain cast nephropathy (LCCN) is a leading cause of acute kidney injury (AKI) in patients with multiple myeloma (MM) and is now defined as a myeloma defining event. While the long-term prognosis has improved with novel agents, short-term mortality remains significantly higher in patients with LCCN especially if the renal failure is not reversed. Recovery of renal function requires a rapid and significant reduction of the involved serum free light chain.